Distal Access designs and develops medical devices to enhance patient care including guidewire controllers, catheter controllers, thrombus macerators, and several others.
The acquired portfolio includes the Resectr tissue resection device, which is a single-use solution that will remove uterine polyps.
Uterine polyps will lead to different symptoms, including abnormal uterine bleeding and infertility.
The Resectr device, which is compatible with a range of hysteroscopes, allows physicians to treat patients with polyps in an office, hospital or ambulatory surgery center.
The device, along with a diagnostic hysteroscope, helps to treat polyps in a single office visit.
Boston Scientific will add Resectr device to its urology and pelvic health business, which includes Symphion system and Genesys HTA system.
Symphion system is used for the removal of uterine tissue and Genesys HTA system ash been developed for the treatment of abnormal uterine bleeding.
Boston Scientific urology and pelvic health president and senior vice president David Pierce said: "The Resectr device is exactly the type of innovation we need to help make healthcare more cost-effective and accessible for physicians and their patients.
"This acquisition is part of our commitment to advance comprehensive solutions for women's health that can help physicians provide high-quality care."
Earlier this month, Boston Scientific acquired tissue retractor system from California-based LumenR for an undisclosed sum.
The LumenR tissue retractor system is currently being developed for use in endoscopic resection of lesions in the colon, esophagus or stomach.
Image: Boston Scientific's corporate headquarters in Marlborough, Massachusetts. Photo: courtesy of Boston Scientific Corporation.
